Coherus Oncology (CHRS) Change in Receivables (2015 - 2026)

Coherus Oncology (CHRS) has 11 years of Change in Receivables data on file, last reported at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 108.41% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at -$38.4 million (up 79.97% YoY), and the FY2025 full-year result was -$93.6 million, up 37.36% from the prior year.
• Change in Receivables fell to $4.3 million in Q1 2026, from $8.3 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $75.3 million in Q3 2023 to a low of -$76.6 million in Q2 2024.
• A 5-year average of -$5.9 million and a median of -$6.0 million in 2022 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables soared 3084.96% in 2023 and tumbled 493.2% in 2025, its largest moves.
• Tracing CHRS's Change in Receivables over 5 years: stood at $18.8 million in 2022, then soared by 134.38% to $44.1 million in 2023, then slumped by 227.85% to -$56.3 million in 2024, then jumped by 114.8% to $8.3 million in 2025, then tumbled by 48.64% to $4.3 million in 2026.
• Business Quant data shows CHRS's Change in Receivables at $4.3 million in Q1 2026, $8.3 million in Q4 2025, and $4.3 million in Q3 2025.